HOME › DRUGS › SOTORASIB
ACTIVE SUBSTANCE / INN

SOTORASIB

Brand name(s): Lumykras, LUMAKRAS
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Carcinoma, Non-Small-Cell Lung
NDA214665
ACTIVE SUBSTANCE
Sotorasib
REGULATORS
FDA · EMA
SPONSORS / MAH
Amgen Europe B.V., AMGEN INC
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
LUMAKRASNDA214665AMGEN INCPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
LumykrasAmgen Europe B.V.Authorised06/01/2022Carcinoma, Non-Small-Cell Lung

FULL INTELLIGENCE ON SOTORASIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →